Promising drug cocktail aims to shrink rare lymphoma before radiation
NCT ID NCT07574528
First seen May 20, 2026 · Last updated Jun 17, 2026 · Updated 8 times
Summary
This study tests a combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation in people newly diagnosed with stage I or II extranodal NK/T-cell lymphoma, a rare cancer of the immune system. The goal is to see how many patients achieve complete remission after treatment. About 47 adults aged 18 and older who have not had prior lymphoma therapy will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NKTCL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, 广东省 - Guangdong Sheng, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.